- Home
- FOLD vs PRCT Comparison
FOLD vs PRCT Comparison
Compare FOLD & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- PRCT
- Stock Information
- Founded
- FOLD 2002
- PRCT 2009
- Country
- FOLD United States
- PRCT United States
- Employees
- FOLD N/A
- PRCT N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- PRCT Medical Specialities
- Sector
- FOLD Health Care
- PRCT Health Care
- Exchange
- FOLD Nasdaq
- PRCT Nasdaq
- Market Cap
- FOLD 2.9B
- PRCT N/A
- IPO Year
- FOLD 2007
- PRCT 2021
- Fundamental
- Price
- FOLD $8.16
- PRCT $58.26
- Analyst Decision
- FOLD Strong Buy
- PRCT Strong Buy
- Analyst Count
- FOLD 9
- PRCT 7
- Target Price
- FOLD $17.00
- PRCT $94.29
- AVG Volume (30 Days)
- FOLD 2.5M
- PRCT 903.6K
- Earning Date
- FOLD 05-08-2025
- PRCT 04-24-2025
- Dividend Yield
- FOLD N/A
- PRCT N/A
- EPS Growth
- FOLD N/A
- PRCT N/A
- EPS
- FOLD N/A
- PRCT N/A
- Revenue
- FOLD $528,294,999.00
- PRCT $224,498,000.00
- Revenue This Year
- FOLD $21.91
- PRCT $46.28
- Revenue Next Year
- FOLD $22.22
- PRCT $32.67
- P/E Ratio
- FOLD N/A
- PRCT N/A
- Revenue Growth
- FOLD 32.29
- PRCT 64.84
- 52 Week Low
- FOLD $7.97
- PRCT $45.56
- 52 Week High
- FOLD $12.65
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- FOLD 30.82
- PRCT 41.71
- Support Level
- FOLD $8.40
- PRCT $56.14
- Resistance Level
- FOLD $8.62
- PRCT $64.38
- Average True Range (ATR)
- FOLD 0.24
- PRCT 2.87
- MACD
- FOLD -0.06
- PRCT 0.64
- Stochastic Oscillator
- FOLD 14.73
- PRCT 33.77
Stock Price Comparison Chart: FOLD vs PRCT
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.